09:55 Jun 6, 2022 |
|
Spanish to English translations [PRO] Medical - Medical (general) / Stage IV colon cancer | |||||||
---|---|---|---|---|---|---|---|
|
|
Summary of answers provided | ||||
---|---|---|---|---|
3 | include |
| ||
2 | Target lesions are still present/detected in retroperitoneal area. =(literally: take, catch) |
|
Discussion entries: 2 | |
---|---|
Target lesions are still present/detected in retroperitoneal area. =(literally: take, catch) Explanation: Management of adverse events during cyclin-dependent ...https://www.ncbi.nlm.nih.gov › articles › PMC6122233 by M Thill · 2018 · Cited by 91 — Cyclin-dependent kinase (CDK) 4/6 inhibitors have shown great results ... a lower rate of hematologic adverse events, including neutropenia. Retroperitoneal Tumors in the Pelvis: A Diagnostic Challenge ...https://www.frontiersin.org › fsurg.2014.00049 › full by WW Wee-Stekly · 2014 · Cited by 25 — Most retroperitoneal tumors are mesodermal in origin and can arise from any tissue type present in the retroperitoneum. -------------------------------------------------- Note added at 12 perc (2022-06-06 10:08:35 GMT) -------------------------------------------------- FOLFOXIRI plus bevacizumab is used as a first-line therapy for patients with unresectable or metastatic colorectal cancer. However, there are no clear recommendations for second-line therapy after FOLFOXIRI plus bevacizumab combination. Here, we describe our planning for the EFFORT study to investigate whether FOLFIRI plus aflibercept has efficacy following FOLFOXIRI plus bevacizumab for mCRC. https://bmccancer.biomedcentral.com/articles/10.1186/s12885-... |
| |
Login to enter a peer comment (or grade) |
include Explanation: encompass |
| |
Login to enter a peer comment (or grade) |
Login or register (free and only takes a few minutes) to participate in this question.
You will also have access to many other tools and opportunities designed for those who have language-related jobs (or are passionate about them). Participation is free and the site has a strict confidentiality policy.